Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180373
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ribera, Jordi | - |
dc.contributor.author | Granada, Isabel | - |
dc.contributor.author | Morgades, Mireia | - |
dc.contributor.author | González, Teresa | - |
dc.contributor.author | Ciudad, Juana | - |
dc.contributor.author | Such, Esperanza | - |
dc.contributor.author | Calasanz, María José | - |
dc.contributor.author | Mercadal, Santiago | - |
dc.contributor.author | Coll, Rosa | - |
dc.contributor.author | González Campos, José | - |
dc.contributor.author | Tormo, Mar | - |
dc.contributor.author | García Cadenas, Irene | - |
dc.contributor.author | Gil, Cristina | - |
dc.contributor.author | Cervera, Marta | - |
dc.contributor.author | Barba, Pere | - |
dc.contributor.author | Costa, Dolors | - |
dc.contributor.author | Ayala, Rosa | - |
dc.contributor.author | Bermúdez, Arancha | - |
dc.contributor.author | Orfao, Alberto | - |
dc.contributor.author | Ribera, Josep Maria | - |
dc.contributor.author | Programa Español de Tratamiento en Hematología (PETHEMA) Group Spanish Society Of Hematology (SEHH) | - |
dc.date.accessioned | 2021-10-04T07:33:36Z | - |
dc.date.available | 2021-10-04T07:33:36Z | - |
dc.date.issued | 2021-09-21 | - |
dc.identifier.issn | 1365-2141 | - |
dc.identifier.uri | http://hdl.handle.net/2445/180373 | - |
dc.description.abstract | The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation). | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1111/bjh.17844 | - |
dc.relation.ispartof | British Journal of Haematology, 2021, vol. 194 | - |
dc.relation.uri | https://doi.org/10.1111/bjh.17844 | - |
dc.rights | cc by-nc-nd (c) Ribera, Jordi et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Pronòstic mèdic | - |
dc.subject.classification | Leucèmia | - |
dc.subject.classification | Citogenètica humana | - |
dc.subject.other | Prognosis | - |
dc.subject.other | Leukemia | - |
dc.subject.other | Human cytogenetics | - |
dc.title | Prognostic heterogeneity of adult B‐cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3‐PBX1 treated with measurable residual disease‐oriented protocols | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-10-01T11:22:49Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34549416 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
bjh.17844.pdf | 160.02 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License